Search hospitals > Ohio > Akron
Children's Hospital Medical Center of Akron
Claim this profileAkron, Ohio 44308
Global Leader in T-Lymphoblastic Leukemia/Lymphoma
Global Leader in Uterine Tumors
Conducts research for Acute Lymphoblastic Leukemia
Conducts research for Cancer
Conducts research for Lymphoma
208 reported clinical trials
5 medical researchers
Summary
Children's Hospital Medical Center of Akron is a medical facility located in Akron, Ohio. This center is recognized for care of T-Lymphoblastic Leukemia/Lymphoma, Uterine Tumors, Acute Lymphoblastic Leukemia, Cancer, Lymphoma and other specialties. Children's Hospital Medical Center of Akron is involved with conducting 208 clinical trials across 405 conditions. There are 5 research doctors associated with this hospital, such as Steven J. Kuerbitz, Erin Wright, Megan Sampson, MD, and Ryan Nofziger, MD.Area of expertise
1T-Lymphoblastic Leukemia/Lymphoma
Global LeaderPhiladelphia chromosome positive
Stage II
NTRK1 positive
2Uterine Tumors
Global LeaderStage I
Stage IV
Stage II
Top PIs
Steven J. KuerbitzChildren's Hospital Medical Center of Akron7 years of reported clinical research
Expert in Uterine Tumors
Expert in Cancer
48 reported clinical trials
97 drugs studied
Erin WrightChildren's Hospital Medical Center of Akron5 years of reported clinical research
Expert in Uterine Tumors
Studies T-Lymphoblastic Leukemia/Lymphoma
42 reported clinical trials
100 drugs studied
Megan Sampson, MDAkron Children's Hospital11 years of reported clinical research
Studies Viral Infections
Studies Infections and Infestations
3 reported clinical trials
3 drugs studied
Ryan Nofziger, MDChildren's Hospital Medical Center of Akron2 years of reported clinical research
Studies Out-of-Hospital Cardiac Arrest
Studies Ischemic Encephalopathy
1 reported clinical trial
1 drug studied
Clinical Trials running at Children's Hospital Medical Center of Akron
Acute Lymphoblastic Leukemia
Acute Myeloid Leukemia
Testicular cancer
Wilms Tumor
T-Lymphoblastic Leukemia/Lymphoma
Uterine Tumors
Acute Leukemia
Brain Tumor
Retinoblastoma
Migraine
Levocarnitine
for Chemotherapy-Related Liver Protection in Leukemia and Lymphoma
This phase III trial compares the effect of adding levocarnitine to standard chemotherapy versus (vs.) standard chemotherapy alone in protecting the liver in patients with leukemia or lymphoma. Asparaginase is part of the standard of care chemotherapy for the treatment of acute lymphoblastic leukemia (ALL), lymphoblastic lymphoma (LL), and mixed phenotype acute leukemia (MPAL). However, in adolescent and young adults (AYA) ages 15-39 years, liver toxicity from asparaginase is common and often prevents delivery of planned chemotherapy, thereby potentially compromising outcomes. Some groups of people may also be at higher risk for liver damage due to the presence of fat in the liver even before starting chemotherapy. Patients who are of Japanese descent, Native Hawaiian, Hispanic or Latinx may be at greater risk for liver damage from chemotherapy for this reason. Carnitine is a naturally occurring nutrient that is part of a typical diet and is also made by the body. Carnitine is necessary for metabolism and its deficiency or absence is associated with liver and other organ damage. Levocarnitine is a drug used to provide extra carnitine. Laboratory and real-world usage of the dietary supplement levocarnitine suggests its potential to prevent or reduce liver toxicity from asparaginase. The overall goal of this study is to determine whether adding levocarnitine to standard of care chemotherapy will reduce the chance of developing severe liver damage from asparaginase chemotherapy in ALL, LL and/or MPAL patients.
Recruiting2 awards Phase 3
Inotuzumab Ozogamicin
for Acute Lymphoblastic Leukemia
This phase III trial studies whether inotuzumab ozogamicin added to post-induction chemotherapy for patients with High-Risk B-cell Acute Lymphoblastic Leukemia (B-ALL) improves outcomes. This trial also studies the outcomes of patients with mixed phenotype acute leukemia (MPAL), and B-lymphoblastic lymphoma (B-LLy) when treated with ALL therapy without inotuzumab ozogamicin. Inotuzumab ozogamicin is a monoclonal antibody, called inotuzumab, linked to a type of chemotherapy called calicheamicin. Inotuzumab attaches to cancer cells in a targeted way and delivers calicheamicin to kill them. Other drugs used in the chemotherapy regimen, such as cyclophosphamide, cytarabine, dexamethasone, doxorubicin, daunorubicin, methotrexate, leucovorin, mercaptopurine, prednisone, thioguanine, vincristine, and pegaspargase or calaspargase pegol work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. This trial will also study the outcomes of patients with mixed phenotype acute leukemia (MPAL) and disseminated B lymphoblastic lymphoma (B-LLy) when treated with high-risk ALL chemotherapy. The overall goal of this study is to understand if adding inotuzumab ozogamicin to standard of care chemotherapy maintains or improves outcomes in High Risk B-cell Acute Lymphoblastic Leukemia (HR B-ALL). The first part of the study includes the first two phases of therapy: Induction and Consolidation. This part will collect information on the leukemia, as well as the effects of the initial treatment, to classify patients into post-consolidation treatment groups. On the second part of this study, patients with HR B-ALL will receive the remainder of the chemotherapy cycles (interim maintenance I, delayed intensification, interim maintenance II, maintenance), with some patients randomized to receive inotuzumab. The patients that receive inotuzumab will not receive part of delayed intensification. Other aims of this study include investigating whether treating both males and females with the same duration of chemotherapy maintains outcomes for males who have previously been treated for an additional year compared to girls, as well as to evaluate the best ways to help patients adhere to oral chemotherapy regimens. Finally, this study will be the first to track the outcomes of subjects with disseminated B-cell Lymphoblastic Leukemia (B-LLy) or Mixed Phenotype Acute Leukemia (MPAL) when treated with B-ALL chemotherapy.
Recruiting2 awards Phase 3
Revumenib + Chemotherapy
for Relapsed/Refractory Leukemia
This phase II trial tests the safety and best dose of revumenib in combination with chemotherapy, and evaluates whether this treatment improves the outcome in infants and young children who have leukemia that has come back (relapsed) or does not respond to treatment (refractory) and is associated with a KMT2A (MLL) gene rearrangement (KMT2A-R). Leukemia is a cancer of the white blood cells, where too many underdeveloped (abnormal) white blood cells, called "blasts", are found in the bone marrow, which is the soft, spongy center of the bones that produces the three major blood cells: white blood cells to fight infection; red blood cells that carry oxygen; and platelets that help blood clot and stop bleeding. The blasts crowd out the normal blood cells in the bone marrow and spread to the blood. They can also spread to the brain, spinal cord, and/or other organs of the body. The leukemia cells of some children have a genetic change in which a gene (KMT2A) is broken and combined with other genes that typically do not interact with one another; this is called "rearranged". This genetic rearrangement alters how other genes are turned on or off in the cell, turning on genes that drive the development of leukemia. Patients with KMT2A rearrangement have higher risk for cancer coming back after treatment. Revumenib is an oral medicine that directly targets the changes that occur in a cell with a KMT2A rearrangement and has been shown to specifically kill these leukemia cells in preclinical laboratory settings and in animals. Drugs used in chemotherapy, such as vincristine, prednisone, asparaginase, fludarabine and cytarabine work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. This trial is being done to find out if the combination of revumenib and chemotherapy would be safe and/or effective in treating infants and young children with relapsed or refractory KMT2A-R leukemia.
Recruiting1 award Phase 2
Similar Hospitals nearby
Select from list below to view details
Frequently asked questions
What kind of research happens at Children's Hospital Medical Center of Akron?
Children's Hospital Medical Center of Akron is a medical facility located in Akron, Ohio. This center is recognized for care of T-Lymphoblastic Leukemia/Lymphoma, Uterine Tumors, Acute Lymphoblastic Leukemia, Cancer, Lymphoma and other specialties. Children's Hospital Medical Center of Akron is involved with conducting 208 clinical trials across 405 conditions. There are 5 research doctors associated with this hospital, such as Steven J. Kuerbitz, Erin Wright, Megan Sampson, MD, and Ryan Nofziger, MD.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.